MaxCyte, Inc.

MXCT

RNS Number: 0855 Z MaxCyte, Inc. 11 May 2023. MaxCyte announces filing of Form 10- Q for the quarterly period ended March 31, 2023. ROCKVILLE, MD, May 11, 2023- MaxCyte, Inc.,, a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and...

MaxCyte, Inc. - Filing of Form 10-Q

·Total revenue of $8.6 million in the first quarter of 2023, a decrease of 26% compared to the first quarter of 2022.. ·Core business revenue of $7.8 million in the first quarter of 2023, a decrease of 19% compared to the first quarter of 2022.. ·We now expect total revenue for 2023 to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and...

MaxCyte, Inc. - First Quarter Financial Results

RNS Number: 7153 O MaxCyte, Inc. 02 February 2023 MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences. ROCKVILLE, MD, February 2, 2023- MaxCyte, Inc.,, a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MaxCyte, Inc. - Notice of Results

RNS Number: 2493 T MaxCyte, Inc. 23 November 2021. Gaithersburg, Maryland, November 23, 2021- M axCyte, Inc.,, a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that...

MaxCyte, Inc. - Purchase of Common Stock

Maxcyte Inc (DI/REG S)

RNS Number: 4680 M MaxCyte, Inc. 30 April 2018. Gaithersburg, Maryland- 30 April 2018: MaxCyte, the global cell-based medicines and life sciences company, gives notice that copies of the 2017 Annual Report and Accounts and the Notice of Annual General Meeting have been sent to Stockholders. Further copies of the Annual Report will be available from the Company...

MaxCyte, Inc. - Notice of AGM and Annual Report

RNS Number: 9826 L MaxCyte, Inc. 25 April 2018. MaxCyte Appoints Dr Claudio Dansky Ullmann as Chief Medical Officer. Gaithersburg, Maryland- 25 April 2018: MaxCyte, the global cell-based medicines and life sciences company, announced today that it has appointed Claudio Dansky Ullmann, MD, a 25+- year expert in clinical oncology and pharmaceutical research, as its...

MaxCyte, Inc. - CMO Appointment

·Revenues increased 14% to $14.0 million. ·Investment in CARMA™ was $7.5 million as the Company prepared and completed the filing of its first investigational new drug application with the US Food and Drug Administration. ·Operating expenses increased to $21.8 million in 2017.

MaxCyte, Inc. - Final Results for Year Ended 31 December 2017

RNS Number: 2054 H MaxCyte, Inc. 06 June 2017. MaxCyte and National Institute of Allergy and Infectious Diseases to. Maryland, USA- 06 June 2017- MaxCyte, Inc. today an nounces it has entered into a Cooperative Research and Development Agreement with the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop treatments...

MaxCyte, Inc. - Research & Development Agreement with NIAID

RNS Number: 7231 G MaxCyte, Inc. 31 May 2017. Maryland, USA- 31 May 2017: MaxCyte announces that, following an exercise of options, 22,435 new shares of common stock of $0.01 each in the Company were issued from the blocklisting facility granted 5 May 2017.. MaxCyte, is a US-based global company dedicated to driving the acceleration of the discovery, development,...

MaxCyte, Inc. - Total Voting Rights

RNS Number: 9212 D MaxCyte, Inc. 02 May 2017. MaxCyte provides notification that an application has been made to the London Stock Exchange for admission to AIM for a block listing of 1,000,000 ordinary shares of common stock of $0.01 each in the Company.. MaxCyte is a US-based global company dedicated to driving the acceleration of the discovery, development,...

MaxCyte, Inc. - Block Listing Application

RNS Number: 3255 D MaxCyte, Inc. 25 April 2017.

MaxCyte, Inc. - Holding(s) in Company

RNS Number: 1821 D MaxCyte, Inc. 25 April 2017. Gaithersburg, Maryland- April 25, 2017: MaxCyte a US-based global company dedicated to driving the acceleration of discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today it will present positive preclinical study results at the American Society...

MaxCyte, Inc. - Presentation of Positive Preclinical Data

RNS Number: 9189 C MaxCyte, Inc. 20 April 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS, OR IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH...

MaxCyte, Inc. - Result of Special Meeting and Issue of Equity

RNS Number: 4800 C MaxCyte, Inc. 13 April 2017. Maryland, USA- 13 April 2017: MaxCyte, a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, gives notice that copies of the 2016 Annual Report and Accounts and the Notice of Annual General...

MaxCyte, Inc. - Notice of AGM and 2016 Annual Report and Accounts

RNS Number: 1963 B MaxCyte, Inc. 31 March 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS, OR IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE,...

MaxCyte, Inc. - Results of Placing

RNS Number: 0996 B MaxCyte, Inc. 31 March 2017 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS, OR IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE,...

MaxCyte, Inc. - Proposed Placing to raise up to approx. £20.0m

RNS Number: 8799 Z MaxCyte, Inc. 20 March 2017. Maryland, USA- 20 March 2017: MaxCyte, a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, today announces its full-year audited results for the year ended 31 December 2016, a pivotal year as it became a...

MaxCyte, Inc. - Full Year Results

RNS Number: 3349 Z MaxCyte, Inc. 14 March 2017. BASEL, Switzerland, CAMBRIDGE, Mass., USA& GAITHERSBURG, Maryland, USA. Mar. 14th, 2017- CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG for...

MaxCyte, Inc. - CRISPR THERAPEUTICS/CASEBIA COMMERCIAL LICENSE

RNS Number: 3008 Y MaxCyte, Inc. 02 March 2017. Maryland, USA- 2 March 2017: MaxCyte, a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, an nounced today it will present results of pre-clinical in vivo research demonstrating the potential of its novel,...

MaxCyte, Inc.

MaxCyte, Inc. - Filing of Form 10-Q

MaxCyte, Inc. - First Quarter Financial Results

MaxCyte, Inc. - Notice of Results

MaxCyte, Inc. - Purchase of Common Stock

Company Profile

Classification

Financials

Financials Data